KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Cost of Revenue: 2010-2022

Historic Cost of Revenue for TherapeuticsMD (TXMD) over the last 13 years, with Dec 2022 value amounting to $1.4 million.

  • TherapeuticsMD's Cost of Revenue fell 70.06% to $106,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.5 million, marking a year-over-year increase of 101.80%. This contributed to the annual value of $1.4 million for FY2022, which is 0.36% down from last year.
  • TherapeuticsMD's Cost of Revenue amounted to $1.4 million in FY2022, which was down 0.36% from $1.4 million recorded in FY2021.
  • In the past 5 years, TherapeuticsMD's Cost of Revenue registered a high of $117.1 million during FY2020, and its lowest value of $1.4 million during FY2022.
  • For the 3-year period, TherapeuticsMD's Cost of Revenue averaged around $40.0 million, with its median value being $1.4 million (2021).
  • As far as peak fluctuations go, TherapeuticsMD's Cost of Revenue spiked by 4,072.59% in 2019, and later plummeted by 98.80% in 2021.
  • Over the past 5 years, TherapeuticsMD's Cost of Revenue (Yearly) stood at $2.7 million in 2018, then soared by 4,072.59% to $114.2 million in 2019, then climbed by 2.47% to $117.1 million in 2020, then slumped by 98.80% to $1.4 million in 2021, then fell by 0.36% to $1.4 million in 2022.